# US 2025/0205306 A1 · Use of follistatin-like 1 (fstl1) in cardiometabolic heart failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205306 A1
- Document ID: US20250205306A1
- Status: Published application
- Kind: A1
- Application number: 18/849,801
- Filed: 2023-03-24
- Published: 2025-06-26
- Earliest claimed: 2022-03-25
- Assignees: Regencor, Inc.
- Applicants: Regencor, Inc.
- Inventors: Thomas B. OKARMA; Pilar RUIZ-LOZANO
- Web page: https://patentgrep.com/patent/US20250205306A1

## CPC

- A61K 38/1709: {from mammals}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 31/12: Antivirals
- C07K 14/4702: {Regulators; Modulating activity}
- A01K 2207/30: Animals modified by surgical methods
- A01K 2227/108: Swine
- A01K 2267/0375: Animal model for cardiovascular diseases
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Provided herein, inter alia, are compositions and kits comprising epicardial-derived paracrine factors, such as follistatin-like 1 (FSTL1), for aiding treatment of cardiometabolic heart failures, as well as methods for using the same.

## Claims

### Claim 1

A method of aiding cardiometabolic heart failure treatment, the method comprising contacting cardiac tissue with a non-glycosylated follistatin-like 1 (FSTL1) polypeptide.

### Claim 2

A method of treating cardiometabolic heart failure, the method comprising contacting cardiac tissue with a non-glycosylated follistatin-like 1 (FSTL1) polypeptide.

### Claim 3

A method of repairing cardiac tissue following cardiometabolic heart failure, the method comprising contacting the cardiac tissue with a non-glycosylated follistatin-like 1 (FSTL1) polypeptide.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the cardiometabolic heart failure is a heart failure with reduced ejection fraction (HFrEF).

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the cardiometabolic heart failure is a diabetic cardiomyopathy.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the FSTL1 decreases heart failure mortality.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the FSTL1 attenuates the development of coronary and cerebral vascular dysfunction.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the FSTL1 improves cardiac function.

### Claim 9 (depends on 8)

The method of claim 8, wherein the FSTL1 reduces heart rate.

### Claim 10 (depends on 8)

The method of claim 8, wherein the FSTL1 does not alter left ventricular volume and systolic or diastolic volume.

### Claim 11 (depends on 8)

The method of claim 8, wherein the FSTL1 prevents left ventricular diastolic dysfunction.

### Claim 12 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the FSTL1 improves ventricular-vascular interactions.

### Claim 13 (depends on 12)

The method of claim 12, wherein the FSTL1 decreases pulmonary congestion.

### Claim 14 (depends on 12)

The method of claim 12, wherein the FSTL1 prevents mismatch between ventricular function and arterial load as a function of decreased contractility.

### Claim 15 (depends on 12)

The method of claim 12, wherein the FSTL1 prevents the narrowing of pulse pressure.

### Claim 16 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the FSTL1 improves coronary and/or peripheral vascular function.

### Claim 17 (depends on 16)

The method of claim 16, wherein the FSTL1 increases blood flow to the heart and skeletal muscles.

### Claim 18 (depends on 16)

The method of claim 16, wherein the FSTL1 attenuates impaired BKCa channel-mediated coronary arteriole dilatory capacity in remote coronary vessels.

### Claim 19 (depends on 16)

The method of claim 16, wherein the FSTL1 attenuates the loss of TXA2-mediated vasoconstriction.

### Claim 20 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the FSTL1 improves mitochondrial function.

### Claim 21 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the FSTL1 reduces necrosis in infarct area.

### Claim 22 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the FSTL1 reduces lung weight.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the FSTL1 is delivered by systemically.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the FSTL1 is delivered endocardially.

### Claim 25 (depends on 24)

The method of claim 24, wherein the endocardial delivery is via a catheter.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the FSTL1 is delivered epicardially.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the FSTL1 is delivered using a drug-eluting stent.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the FSTL1 is delivered by a hydrogel embedded or seeded with the FSTL1.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the FSTL1 is delivered by a collagen patch embedded or seeded with the FSTL1.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the FSTL1 is delivered via an osmotic pump.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the FSTL1 is delivered as a single or several subcutaneous bolus.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the FSTL1 is delivered by a coronary infusion.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the FSTL1 is expressed in the heart by use of modified RNAs (modRNAs).

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the FSTL1 is expressed by genomic editing.

### Claim 35 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 24-34, wherein the cardiac tissue is contacted from one or more of an epicardial site, an endocardial site, and/or through direct injection into the myocardium.

### Claim 36 (depends on 33, 34)

The method of any one of claims 33-34, the method further comprising an inhibitor of FSTL1 glycosylation.

### Claim 37 (depends on 36)

The method of claim 36, wherein the inhibitor of FSTL1 glycosylation comprises tunicamycin.
